“…The cardinal neuropathological features of AD include extracellular accumulations of amyloid beta (Aβ) peptide [2], neurofibrillary tangles (NFTs) of hyper-phosphorylated tau proteins [3], neuropil threads, dystrophic neuritis [4,5], astrogliosis, microglial activation [6], and overall neurodegeneration of the brain [6][7][8]. Several hypotheses about cholinergic system dysfunction [9], Aβ deposits, oxidative stress [10], inflammatory pathways [11], calcium signaling dysfunction [12], hormone imbalance [13], and genetic components [14] have been considered to play important roles in the occurrence and development of AD, although the etiology of this disease is still not precisely known [15]. In addition, although several therapies have been used as compensation for the cholinergic neuronal loss and reduction or prevention of amyloid/tau aggregation and toxicity, such as gene therapy, vaccines, anti-inflammatory agents [16], cholesterol-lowering agents, anti-oxidants [17], and hormone therapy [18] for AD, these single targeted therapies have often been unsuccessful [19,20].…”